THE WIRE · № 61360
Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026
01 THE MACHINE READ
WHY IT MATTERS.
Pipeline data readouts can shift sentiment on Lundbeck's movement-disorder franchise, but no efficacy or revenue figures are given here.
Lundbeck pipeline update, no financials disclosed
Phase III MASCOT data at MDS 2026
No efficacy or sales numbers in release
FULL DISPATCH
Late-breaking Phase III MASCOT oral presentation will characterize the clinical profile and diversity of participants in Lundbeck's ongoing global Phase III trial investigating amlenetug in multiple system atrophy (MSA) New research across clinical trial endpoints, biomarkers, diagnostic...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Phase 3 results posted: Atacicept in Subjects With IgA Nephropathy — Vera Therapeutics, Inc.2026-10-01 12:00 UTC
Phase 3 results posted: A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia — Biosplice Therapeutics, Inc.2026-10-01 12:00 UTC
Phase 3 results posted: Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) — BioXcel Therapeutics Inc2026-10-01 12:00 UTC
Phase 3 results posted: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis — Abcuro, Inc.2026-10-01 12:00 UTC
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-01 17:58 UTC
Quadria-backed Maxivision confidentially files for India IPO2026-10-01 23:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.